This week, devicemaker Medtronic will report first-quarter earnings for fiscal 2015. While the financial results are important, many analysts will tune in to hear more about the company's pending acquisition of Covidien.
Minneapolis-based Medtronic said in June that it planned to buy Covidien, a surgical- and medical-device supplier based in Ireland, for almost $43 billion in cash and stock. The deal is expected to close by the end of the year.
What turned most heads was Medtronic's controversial plan to move its official headquarters from Minneapolis to Dublin, thereby reaping a lower corporate tax rate. The nominal U.S. rate is about 35%, though few companies pay that amount.